Cancer-related inflammation by A. Mantovani et al.
Links between cancer and inflammation were first made in the nine-
teenth century, on the basis of observations that tumours often arose at 
sites of chronic inflammation and that inflammatory cells were present 
in biopsied samples from tumours1. The idea that these processes are 
connected was out of favour for more than a century, but there has been 
a recent resurgence in interest. Several lines of evidence1–4 (Box 1) — 
based on a range of findings, from epidemiological studies of patients to 
molecular studies of genetically modified mice — have led to a general 
acceptance that inflammation and cancer are linked.
Epidemiological studies have shown that chronic inflammation predis-
poses individuals to various types of cancer. It is estimated that underlying 
infections and inflammatory responses are linked to 15–20% of all deaths 
from cancer worldwide1. There are many triggers of chronic inflammation 
that increase the risk of developing cancer. Such triggers include microbial 
infections (for example, infection with Helicobacter pylori is associated 
with gastric cancer and gastric mucosal lymphoma), autoimmune dis-
eases (for example, inflammatory bowel disease is associated with colon 
cancer) and inflammatory conditions of unknown origin (for example, 
prostatitis is associated with prostate cancer). Accordingly, treatment with 
non-steroidal anti-inflammatory agents decreases the incidence of, and 
the mortality that results from, several tumour types5–7. 
The hallmarks of cancer-related inflammation include the presence 
of inflammatory cells and inflammatory mediators (for example, chemo-
kines, cytokines and prostaglandins) in tumour tissues, tissue remod-
elling and angiogenesis similar to that seen in chronic inflammatory 
responses, and tissue repair. These signs of ‘smouldering’ inflammation2 
are also present in tumours for which a firm causal relationship to inflam-
mation has not been established (for example, breast tumours). Indeed, 
inflammatory cells and mediators are present in the microenvironment 
of most, if not all, tumours, irrespective of the trigger for development. 
Studies of genetically modified mice, adoptive-transfer experiments 
in mice, and analyses of human tumours have allowed researchers to 
begin to unravel the molecular pathways that link inflammation and 
cancer. Here we review current knowledge of the molecular and cel-
lular pathways that link inflammation and cancer, and we describe how 
these pathways suppress effective antitumour immunity during tumour 
progression. We also discuss how cancer-related inflammation affects 
many aspects of malignancy, including the proliferation and survival 
of malignant cells, angiogenesis (which is required for the survival of 
cells within tumours of a certain size), tumour metastasis, and tumour 
response to chemotherapeutic drugs and hormones.
Advances in understanding the genetic pathways involved in cancer 
have led to the development of a range of therapies that target malignant 
cells. Understanding the pathways involved in cancer-related inflamma-
tion could enable the development of synergistic therapies that target 
‘the other half of the tumour’ — that is, the inflammatory components 
of the microenvironment. Preclinical and early clinical studies are now 
suggesting how this might be achieved. However, despite considerable 
progress, important questions remain unanswered, as we discuss in the 
final section of this Review.
Connecting inflammation and oncogenes
The connection between inflammation and cancer can be viewed as 
consisting of two pathways: an extrinsic pathway, driven by inflamma-
tory conditions that increase cancer risk (such as inflammatory bowel 
disease); and an intrinsic pathway, driven by genetic alterations that 
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• Inflammatory diseases increase the risk of developing many types 
of cancer (including bladder, cervical, gastric, intestinal, oesophageal, 
ovarian, prostate and thyroid cancer).
• Non-steroidal anti-inflammatory drugs reduce the risk of developing 
certain cancers (such as colon and breast cancer) and reduce the 
mortality caused by these cancers.
• Signalling pathways involved in inflammation operate downstream 
of oncogenic mutations (such as mutations in the genes encoding RAS, 
MYC and RET).
• Inflammatory cells, chemokines and cytokines are present in the 
microenvironment of all tumours in experimental animal models and 
humans from the earliest stages of development.
• The targeting of inflammatory mediators (chemokines and 
cytokines, such as TNF-α and IL-1β), key transcription factors involved 
in inflammation (such as NF-κB and STAT3) or inflammatory cells 
decreases the incidence and spread of cancer. 
• Adoptive transfer of inflammatory cells or overexpression of 
inflammatory cytokines promotes the development of tumours.
Box 1 | The evidence that links cancer and inflammation
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cause inflammation and neoplasia (such as oncogenes) (Fig. 1). The 
intrinsic pathway was uncovered when addressing why inflammatory 
cells and mediators are present in the microenvironment of most, if 
not all, tumours and therefore are present in cases for which there is no 
epidemiological basis for inflammation. This finding raised the ques-
tion of whether the genetic events that cause neoplasia in these cases are 
responsible for generating an inflammatory environment. This ques-
tion has been addressed only recently, by using preclinical and clinical 
settings in which various oncogenetic mechanisms can be assessed. 
An example of this type of study involves protein tyrosine kinases, which 
are encoded by prototypical transforming oncogenes. A useful clinical 
setting in which to explore the connection between these oncogenes and 
an inflammatory microenvironment is human papillary thyroid carci-
noma. Rearrangement of the chromosome on which the gene encoding 
the protein tyrosine kinase RET is located (also referred to as the RET/PTC 
rearrangement) is a frequent early event in the pathogenesis of papillary 
thyroid carcinoma and is a necessary and sufficient event for this cancer 
to develop. In an appropriate cellular context, which is provided by freshly 
isolated human thyrocytes, the activation of RET induces a transcriptional 
program that is similar to that which occurs during inflammation8 (Fig. 2). 
The transcriptome of cells in which RET has been activated includes mes-
senger RNA encoding various factors: colony-stimulating factors (CSFs), 
which promote the survival of leukocytes and their recruitment from the 
blood to the tissues; interleukin 1β (IL-1β), one of the main inflammatory 
cytokines; cyclooxygenase 2 (COX2), which is frequently expressed by 
cancerous cells and is involved in the synthesis of prostaglandins; chemo-
kines that can attract monocytes and dendritic cells (CC-chemokine 
ligand 2 (CCL2) and CCL20); chemokines that promote angiogenesis 
(such as IL-8; also known as CXC-chemokine ligand 8 (CXCL8)); the 
chemokine receptor CXC-chemokine receptor 4 (CXCR4), which binds 
to CXCL12; extracellular-matrix-degrading enzymes; and the adhesion 
molecule lymphocyte selectin (L-selectin). Key protein components of the 
RET-activated ‘inflammatory’ program were found in tumour specimens 
taken by biospy, and larger amounts of these inflammatory molecules 
were found in the primary tumours of patients with lymph-node metas-
tasis than in primary tumours in the absence of lymph-node metastasis8,9. 
These results show that an early genetic event that is necessary and suf-
ficient for the development of a human tumour directly promotes the 
build-up of an inflammatory microenvironment8. Although these8,9 and 
other results10 connect the activation of protein-tyrosine-kinase-encoding 
oncogenes to inflammation, the precise roles of the various components 
of the inflammatory microenvironment in the progression of tumours 
remain to be defined.
Members of the RAS family are the most frequently mutated domi-
nant oncogenes in human cancer, and activated oncogenic components 
of the RAS–RAF signalling pathway, in turn, induce the production of 
tumour-promoting inflammatory chemokines and cytokines11–13. Another 
oncogene, MYC, encodes a transcription factor that is over expressed in 
many human tumours; deregulated expression of this gene initiates and 
maintains key aspects of the tumour phenotype. In addition to promo-
ting cell-autonomous proliferation, MYC instructs the remodelling 
of the extracellular microenvironment, with inflammatory cells and 
mediators having important roles in this process. In a mouse model of 
MYC-dependent cancer of the β-cells (which are insulin-producing pan-
creatic islet cells), the first wave of angiogenesis results from MYC-induced 
production of the inflammatory cytokine IL-1β14. The MYC-activated 
transcriptional program also elicits the production of several chemokines 
that recruit mast cells. Mast cells have long been known to drive angio-
genesis, and in this case (following IL-1β) they sustain new blood-vessel 
formation and tumour growth15. 
These studies of RAS family members and MYC show that dominant 
oncogenes promote the formation of a tumour-promoting tissue micro-
environment (the intrinsic pathway), but the findings do not address 
the issue of the interplay between oncogenes and inflammatory con-
ditions that increase the risk of developing cancer (the extrinsic path-
way) (Fig. 1). This interplay is likely to occur in pancreatic carcinoma, 
in which both pancreatitis and mutations in the gene encoding K-RAS 
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Figure 1 | Pathways that connect inflammation and cancer. Cancer and 
inflammation are connected by two pathways: the intrinsic pathway and 
the extrinsic pathway. The intrinsic pathway is activated by genetic events 
that cause neoplasia. These events include the activation of various types of 
oncogene by mutation, chromosomal rearrangement or amplification, and 
the inactivation of tumour-suppressor genes. Cells that are transformed 
in this manner produce inflammatory mediators, thereby generating 
an inflammatory microenvironment in tumours for which there is no 
underlying inflammatory condition (for example, breast tumours). By 
contrast, in the extrinsic pathway, inflammatory or infectious conditions 
augment the risk of developing cancer at certain anatomical sites (for 
example, the colon, prostate and pancreas). The two pathways converge, 
resulting in the activation of transcription factors, mainly nuclear 
factor-κB (NF-κB), signal transducer and activator of transcription 3 
(STAT3) and hypoxia-inducible factor 1α (HIF1α), in tumour cells. 
These transcription factors coordinate the production of inflammatory 
mediators, including cytokines and chemokines, as well as the production 
of cyclooxygenase 2 (COX2) (which, in turn, results in the production of 
prostaglandins). These factors recruit and activate various leukocytes, 
most notably cells of the myelomonocytic lineage. The cytokines activate 
the same key transcription factors in inflammatory cells, stromal cells 
and tumour cells, resulting in more inflammatory mediators being 
produced and a cancer-related inflammatory microenvironment 
being generated. Smouldering cancer-related inflammation has many 
tumour-promoting effects.
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are frequently found. In a relevant mouse model, adult mice are resistant 
to mutated Kras-induced pancreatic carcinogenesis11. Both mild chronic 
pancreatitis (possibly mirroring the clinical epidemiology) and mutated 
Kras are required to induce pancreatic intra-epithelial neoplasia and 
invasive ductal carcinoma11. Thus, although the RAS–RAF pathway12,13 
can drive tumour-promoting inflammation to a certain extent, an extrinsic 
inflammatory condition (pancreatitis) is needed to drive carcinogenesis 
in mice and presumably in humans.
Tumour-suppressor proteins can also regulate the production of inflam-
matory mediators. Examples of such proteins are von Hippel-Lindau 
tumour suppressor (VHL), transforming growth factor-β (TGF-β) and 
phosphatase and tensin homologue (PTEN)16–20. VHL is a component of a 
molecular complex that targets the transcription factor hypoxia-inducible 
factor 1α (HIF1α) for degradation. HIF1α promotes the cellular and tissue 
response to hypoxia, including angio genesis. It also functionally interacts 
with the transcription factor nuclear factor-κB (NF-κB) (discussed later), 
resulting in the production of the major inflammatory cytokine tumour-
necrosis factor-α (TNF-α) and the chemokine receptor CXCR4 in human 
renal-cell carcinoma cells, as well as in other malignant cell types2,16,19,20. 
The production of CXCR4 is particularly relevant, because CXCR4 expres-
sion is frequently upregulated in human cancer and CXCR4 is involved in 
metastasis16 (discussed later). 
Recent evidence from a mouse model of cancer links TGF-β, a tumour-
suppressor protein that is frequently involved in the progression of human 
cancer, to tumour-promoting inflammation21. In an animal model of 
breast carcinoma, inactivation of the gene encoding the type II TGF-β 
receptor (which initiates carcinogenesis by preventing the actions of 
TGF-β) unleashes the production of CXCL5 and CXCL12. These chemo-
kines attract cells known as myeloid-derived suppressor cells (MDSCs), 
which belong to the myelomonocytic lineage. MDSCs are potent suppres-
sors of the adaptive immune response to tumours and directly facilitate 
metastasis. It will be important to assess whether this pathway occurs in 
human tumours in which the TGF-β receptor is involved. 
Thus, the various types of oncogene (such as those encoding pro-
tein tyrosine kinases, RAS and RAF, transcription factors and tumour-
suppressor proteins), irrespective of their molecular class or mode of 
action, all coordinate inflammatory transcriptional programs. And 
these oncogene-coordinated inflammatory responses seem to have 
aspects in common: a link to angiogenesis, and the recruitment of cells 
of myelomonocytic origin. Several issues remain to be fully elucidated, 
including which components of inflammation are essential and which 
are redundant, the relative importance of these components in carcino-
genesis in different tissues, and the relevance of these components to 
different types of cancer in humans. 
Key factors in cancer-related inflammation 
In the panoply of molecules involved in cancer-related inflammation, 
key endogenous (intrinsic) factors can be identified. These include tran-
scription factors (such as NF-κB and signal transducer and activator of 
transcription 3 (STAT3)) and major inflammatory cytokines (such as 
IL-1β, IL-6, IL-23 and TNF-α)4,22–26. The main inflammatory cytokines 
were discussed earlier, so this section focuses on transcription factors. 
NF-κB is a key coordinator of innate immunity and inflammation, and 
has emerged as an important endogenous tumour promoter4. NF-κB is 
crucial both in the context of tumour or potential tumour cells and in 
the context of inflammatory cells. In these cell types, NF-κB operates 
downstream of the sensing of microorganisms or tissue damage by the 
Toll-like receptor (TLR)–MyD88 signalling pathway, and by signalling 
pathways mediated by the inflammatory cytokines TNF-α and IL-1β. In 
addition, NF-κB can be activated as a result of cell-autonomous genetic 
alterations (amplification, mutations or deletions)27 in tumour cells.
In tumour cells and epithelial cells at risk of transformation by carcin-
ogens, as well as in inflammatory cells, NF-κB activates the expression of 
genes encoding inflammatory cytokines, adhesion molecules, enzymes 
in the prostaglandin-synthesis pathway (such as COX2), inducible nitric 
oxide synthase (iNOS; also known as NOS2) and angiogenic factors. 
In addition, one of the important functions of NF-κB in tumour cells 
or cells targeted by carcinogenic agents is promoting cell survival, by 
inducing the expression of anti-apoptotic genes (such as BCL2). There 
is also accumulating evidence of interconnections and compensatory 
pathways between the NF-κB and HIF1α systems28–30, linking innate 
immunity to the response to hypoxia.
There is unequivocal evidence that NF-κB is involved in tumour ini-
tiation and progression in tissues in which cancer-related inflammation 
typically occurs (such as the gastrointestinal tract and the liver)31,32. This 
evidence is based on various genetic studies, such as tissue-specific tar-
geting of genes that encode components of the IκB kinase (IKK) com-
plex. This complex phosphorylates inhibitor of NF-κB (IκB), causing 
it to dissociate from NF-κB and allowing NF-κB to translocate to the 
nucleus, where it can exert its function as a transcription factor. It should 
be noted that genetic targeting of NF-κB in liver epithelial cells can have 
divergent effects in different models of carcinogenesis, possibly depend-
ing on the balance between promoting apoptosis that has already been 
initiated and triggering compensatory cell proliferation32,33.
The NF-κB pathway is tightly controlled by inhibitors that func-
tion at various stages of the pathway. An example is TIR8 (also known 
as SIGIRR), a member of the IL-1-receptor family. TIR8 has a single 
immuno globulin domain, a long cytoplasmic tail, and a Toll/IL-1 recep-
tor (TIR) domain that differs from that of other members of the IL-1-
receptor family. It inhibits signalling through TLRs and the IL-1 receptor 
and is highly expressed in the intestinal mucosa. Deficiency in the gene 
that encodes TIR8 is associated with increased susceptibility to intestinal 
inflammation and carcinogenesis34,35. Thus, the balance of inhibitors and 
activators tunes the extent to which the NF-κB pathway operates as an 
endogenous tumour promoter.
Support for the connection between cancer and inflammation is 
further strengthened by studies of the role of NF-κB in tumour-infiltra-
ting leukocytes. For example, by using the strategy mentioned above, 
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Figure 2 | Oncogenes and cancer-related inflammation. A class of 
oncogenes encodes protein tyrosine kinases that are persistently activated 
in a ligand-independent manner as a result of mutation or chromosomal 
rearrangement. RET is representative of these activated oncogenes. 
A chromosomal rearrangement that affects RET is a frequent early 
event in the pathogenesis of human papillary thyroid carcinoma. In 
human thyrocytes maintained in short-term culture, RET activates an 
inflammatory transcriptional program, the components of which are found 
in tumours obtained from patients. The inflammatory mediators that are 
produced in response to this program, together with their effects on tumour 
cells and inflammatory cells, are indicated. CCL, CC-chemokine ligand; 
CSF, colony-stimulating factor; CXCL12, CXC-chemokine ligand 12; 
CXCR4, CXC-chemokine receptor 4; IL-8, interleukin 8; L-selectin, 
lymphocyte selectin; MMP, matrix metalloproteinase; UPA, urokinase-type 
plasminogen activator.
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myeloid-lineage-specific inactivation of the gene encoding IKK-β was 
found to inhibit cancer-related inflammation in the intestine, as well as 
colitis-associated cancer, unequivocally showing that inflammatory cells 
are involved in carcinogenesis in this tissue31. In established, advanced 
tumours, which typically have a microenvironment of smouldering 
inflammation2, tumour-associated macrophages (TAMs) have delayed 
and defective NF-κB activation36. Evidence suggests that homodimers 
of the p50 subunit of NF-κB (a negative regulator of the NF-κB pathway) 
are responsible for this sluggish activation of NF-κB in TAMs and for the 
protumour phenotype of these cells37. Thus, NF-κB seems to function as 
a ‘rheostat’ whose function can be tuned to different levels, a property 
that enables the extent of inflammation to be regulated. Such regulation 
allows the vigorous inflammation (for example, in inflammatory bowel 
disease) that predisposes individuals towards developing cancer to be 
sustained, and enables TAMs to sustain the smouldering inflammatory 
microenvironment present in established metastatic neoplasia. 
Similar to NF-κB, STAT3 is a point of convergence for numerous 
oncogenic signalling pathways22. This transcription factor is consti-
tutively activated both in tumour cells and in immune cells, and is 
involved in oncogenesis and inhibition of apoptosis38. The activation 
of STAT3 in tumour cells has also been shown to increase the capacity 
of tumours to evade the immune system, by inhibiting the maturation of 
dendritic cells39 and suppressing the immune response40.
Tumour-infiltrating leukocytes
A leukocyte infiltrate, varying in size, composition and distribution, is 
present in most, if not all, tumours. Its components include TAMs and 
related cell types, mast cells and T cells. There is evidence (based on 
adoptive-transfer studies, cell-depletion studies, clinical correlations 
and gene-manipulation studies) that each of these bone-marrow-
derived components can be involved in carcinogenesis and/or tumour 
invasion and metastasis41–44.
In this section, we focus on TAMs. TAMs are an important com-
ponent of the leukocyte infiltrate, and studies of TAMs formed the 
basis for the model that leukocyte infiltrates are involved in tumour 
progression. Plasticity and diversity are hallmarks of mononuclear 
phagocytes. In addition to conventional TAMs, related cell popula-
tions (for example, a TIE2-expressing monocyte subset, MDSCs and 
myeloid dendritic cells) have been linked to a protumour inflammatory 
microenvironment45,46. The ontogenetic relationship between these cell 
types and their relative importance in the context of tumours remain 
to be elucidated.
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Figure 3 | Hormones and inflammation. Hormones and inflammation are 
each involved in a classic pathway that promotes tumour development. 
a, Liver. The carcinogen diethylnitrosamine (DEN) can activate the MyD88 
signalling pathway in Kupffer cells (a type of macrophage) in the liver 
(presumably through TLRs or IL-1 receptors), resulting in the production 
of IL-6 (ref. 61). IL-6, in turn, promotes inflammation, tissue damage, 
compensatory cell proliferation and, ultimately, formation of a liver tumour. 
Oestrogens interfere with the activity of NF-κB, the transcription factor 
that regulates IL-6 production, and thereby protect against carcinogenesis61. 
b, Prostate. Patients with prostate tumours are often treated with drugs 
known as selective androgen-receptor modulators (SARMs), which reduce 
the growth-promoting effects of male sex hormones (androgens) on the 
tumour. TAMs can, however, produce IL-1β, which results in the desired 
action of SARMs being reversed, from inhibitors of androgen-receptor-
signalling-induced gene expression (as intended) to activators. This process 
involves TAB2 (TGF-β-activated kinase 1 (TAK1)-binding protein 2), 
a sensor of inflammatory signals. TAB2 is a component of a co-repressor 
complex that includes the nuclear-receptor co-repressor (NCOR) and 
a histone deacetylase (HDAC). IL-1β-mediated signalling results in the 
phosphorylation of TAB2, thereby lifting the repression of transcription. 
SARMs thus promote tumour-cell proliferation instead of inhibiting it. 
(Figure modified, with permission, from ref. 92.)
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TAMs and related cell types in mouse and human tumours generally 
have an M2 phenotype, which is oriented towards promoting tumour 
growth, remodelling tissues, promoting angiogenesis and suppressing 
adaptive immunity 45,47. Signals that are derived from regulatory T cells 
present in tumours or from the tumour cells themselves (including 
macrophage CSF (M-CSF), IL-10 and TGF-β)45,47,48 might account for 
this polarization to the M2 phenotype of macrophages that have been 
recruited into tumours. However, a stringent analysis of the molecular 
mechanisms responsible for this functional polarization during tumour 
progression has not been carried out.
Leukocyte infiltration is also interconnected with angiogenesis, which 
is required in tumours of a certain size. The pro-angiogenic protein vas-
cular endothelial growth factor (VEGF) and related molecules are potent 
monocyte attractants and contribute to the recruitment of monocytes into 
primary tumours and the metastatic niche46,49–51. In turn, the recruited 
leukocytes provide an indirect (VEGF-independent) pathway of angio-
genesis, through the secretion of pro-angiogenic factors41,51–55. It is possible 
therefore that the inhibition of leukocyte recruitment will improve the 
activity of current anti-angiogenic therapies for patients with cancer.
Cancer-related inflammation and adaptive immunity
There is strong evidence from genetic studies of mouse models that 
cells of the adaptive immune system carry out surveillance and can 
eliminate nascent tumours (a process called immuno-editing)56. Innate 
immune responses, which manifest as inflammation, are crucial for 
the initiation of adaptive immune responses. Therefore, the seemingly 
divergent effects of inflammation and immuno-editing are paradoxical. 
Yet, a recent study in mice shows that the TLR adaptor MyD88 (which 
is involved in innate immune responses) has a key role in promoting 
tumour development and that inflammation-induced carcinogenesis 
and immuno-editing can occur in the same tumour model57. 
Another aspect of the complex interplay between adaptive immu-
nity and cancer-related inflammation was shown by studies in a mouse 
model of cancer caused by human papilloma virus. In this system, anti-
bodies are deposited in the tumour stroma. These antibodies then func-
tion as a ‘remote-control system’, binding to unidentified molecules in 
the extracellular matrix and thereby activating inflammatory responses 
that promote cancer progression58. 
In clinically overt neoplasia, effective adaptive immune responses 
are suppressed through the activation of several pathways. For exam-
ple, the differentiation and activation of dendritic cells, which are the 
key initiators of adaptive immune responses, are inhibited by signals 
(such as IL-10) present in the tumour microenvironment. In addition, 
tumours are frequently infiltrated by regulatory T cells, which suppress 
both adaptive and innate immune responses. And MDSCs proliferate 
in tumour-bearing hosts; these cells, as well as conventional TAMs, are 
potent suppressors of antitumour immunity46,47. Thus, in cancer-related 
inflammation, multiple pathways are set in motion in to suppress effec-
tive antitumour immunity in established tumours. The interplay between 
these pathways, their hierarchy, and whether they can be targeted for 
therapy remain largely to be determined.
Cancer-related inflammation and sex hormones
Sex steroid hormones mediate a classic, clinically relevant pathway of 
tumour promotion in breast and prostate cancer and have been a target for 
therapeutic intervention since George Beatson’s discovery of hormone-
dependent breast cancer at the end of the nineteenth century59.
Recent studies, however, have uncovered an unexpected relationship 
between sex steroid hormones and cancer (Fig. 3). For carcinoma of the 
prostate, which is an androgen-dependent tumour, sensitivity to stimula-
tion with hormones is regulated by selective androgen-receptor modula-
tors. The inflammatory cytokine IL-1β, which is produced by macrophages 
in the tumour microenvironment, converts these receptor modulators from 
being inhibitory to stimulatory60. It has long been known that females are 
less susceptible to cancer at sites, such as the liver, that are not conventional 
target organs of sex steroid hormones. After studies of a mouse model of 
liver carcinogenesis, Willscott Naugler et al.61 recently reported that the 
sex difference in tumour susceptibility resulted from a downregulation 
of IL-6 production by macrophages in response to oestrogens. In add ition, 
in male mice, IL-6 production was triggered to a much greater extent in 
response to carcinogen-mediated tissue damage (which induces IL-6 
production by activating MyD88-dependent TLR- and/or IL-1-receptor 
signalling pathways). Thus, connections are emerging between the two 
classic tumour-promoting pathways — inflammation and sex steroid hor-
mones — bringing together the pioneering efforts of Beatson and Rudolf 
Virchow in studying inflammatory cells in tumours.
Inflammatory pathways in invasion and metastasis
Most studies of the mechanisms of cancer-related inflammation have 
focused on the early stages of cancer, but inflammatory mediators and 
cells are also involved in the migration, invasion and metastasis of 
malignant cells. 
Chemokine receptors and their ligands direct the movement of cells 
during inflammation, cancer and the maintenance of tissue homeostasis, 
by affecting cell motility, invasiveness and survival16. On transforma-
tion, many cells start to express chemokine receptors and thereby use 
chemokines to aid in their migration to, and survival at, sites that are 
distant from the original tumour16,62,63. For example, the chemokine 
receptor CXCR4 and its ligand CXCL12 are important for cell move-
ment in both homeostatic and disease states63. CXCR4 is frequently 
expressed by malignant cells16, and the amount of CXCR4 expressed by 
primary human tumours correlates with the extent to which metastasis 
to the lymph nodes occurs in colorectal, breast, liver and oesophageal 
cancer64–66. Other functional chemokine receptors (including CX3C-
chemokine receptor 1 (CX3CR1), CC-chemokine receptor 1 (CCR1), 
CCR7, CCR9, CCR10, CXCR1, CXCR2, CXCR3, CXCR5 and CXCR7) 
are also expressed by malignant cells from a variety of tissues and are 
implicated in organ-specific metastasis67–72; for example, the expres-
sion of CCR7 correlates with lymph-node metastasis, and expression 
of CCR9 with metastasis of melanoma to the small intestine. Malignant 
melanoma cells express many of the above receptors, perhaps explaining 
why melanomas are highly metastatic. 
How do malignant cells acquire the ability to express chemokine recep-
tors? Several mechanisms have been defined. Autocrine and paracrine 
extracellular signals, as well as genetic and epigenetic alterations, might 
each contribute to this change. For example, the previously discussed 
mutation in VHL and the chromosomal rearrangement that affects RET 
induce the expression of CXCR4 on initiated cells. Regardless of the 
mechanism, it is clear that acquisition of chemokine-receptor expression 
is a common attribute of malignant cells of epithelial or mesenchymal 
origin that do not normally express these receptors and that this can 
occur even at the early stages of malignancy65. 
The invasive capacity of malignant cells can increase in the presence of 
inflammatory cytokines such as TNF-α, IL-1β and IL-6 (ref. 2), possibly 
as a result of the upregulation of chemokine-receptor expression elicited 
by these cytokines73. For example, autocrine TNF-α-mediated signal-
ling upregulates the expression of functional CXCR4 by ovarian cancer 
cells74, and stable knockdown of mRNA encoding this cytokine reduces 
the expression of both CXCR4 and its ligand CXCL12 by the malignant 
cells, inhibiting colonization of the peritoneal cavity, angiogenesis and 
spread to sites distant from the peritoneal cavity73. TNF-α is also a potent 
stimulator of epithelial–mesenchymal transition by breast cancer cells75, 
as is activation of NF-κB signalling. 
A further link between NF-κB signalling and metastasis was found by 
studying a genetic model of prostate cancer in mice, in which inactivation 
of the gene encoding a major component of the NF-κB signalling pathway, 
IKK-α, was found to reduce metastatic spread76. The mechanism by which 
this occurs was found to involve activation of receptor activator of NF-κB 
(RANK) at the surface of malignant prostate epithelial cells in a paracrine 
manner, by RANK ligand derived from the leukocytes infiltrating the pri-
mary tumours. IKK-α, which is involved in the RANK signalling pathway, 
then inhibited expression of the meta stasis-suppressor protein maspin, 
hence promoting the metastatic phenotype. Therefore, removing IKK-α 
had the opposite effect. It would be interesting to determine whether 
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chemokine ligands and their receptors also contribute to the effects of 
IKK-α and whether IKK-α is implicated in other metastatic pathways.
Other cells within the tumour also affect processes in the later 
stages of cancer. TAMs have been described as “obligate partners for 
tumour-cell migration, invasion and metastasis”77. The first experi-
ments to show this conclusively involved a genetic model of breast 
cancer in macrophage-deficient mice44. The tumours developed nor-
mally but were unable to form pulmonary metastases in the absence 
of macrophages. The mechanism by which metastasis occurs in this 
case involves a paracrine loop of tumour-cell M-CSF and macro-
phage epidermal growth factor44, with intravasation assisted by direct 
interactions between tumour cells and TAMs78. 
In addition, inflammatory macrophages increase peritoneal dissemina-
tion of tumour cells and metastatic spread in an ovarian cancer model79. 
The ability of macrophages to aid in ovarian tumour-cell migration and 
invasion can also be modelled in vitro48,80. Co-culture of macrophages 
with tumour cells was shown to increase their invasive capacity in an 
NF-κB-dependent and TNF-α-dependent manner.
In summary, chemokines and cytokines coordinate autocrine and 
paracrine interactions between malignant cells and infiltrating leuko-
cytes. These interactions increase the migration, invasion and survival of 
malignant cells. They also affect the growth of the primary tumour and the 
ability of tumour cells to colonize the metastatic niche16,63,67,81 (Fig. 4). 
Cancer-inhibitory inflammation
Although numerous experimental and clinical results point to inflam-
mation having protumour activity, some evidence does not fit into 
this general pattern. For example, a marked chronic inflammatory 
response such as that in psoriasis is not associated with an increased 
risk of developing skin cancer82. Also, in certain tumours or subsets of 
tumours, the presence of inflammatory cells is associated with better 
prognosis (for example, eosinophils in colon tumours, and TAMs in a 
subset of breast tumours and pancreatic tumours). These observations 
are likely to reflect that inflammatory cells can destroy tumour cells, in 
addition to normal tissue cells41. For example, appropriately activated 
macrophages, a prototypical component of cancer-related inflamma-
tion, can kill tumour cells and elicit cancer-destructive inflammatory 
responses centred on the blood-vessel wall, although in most cases 
their tumour-promoting properties prevail41. Evidence indicates that 
NF-κB is important in determining this balance between the protumour 
and antitumour properties of macrophages37,83, thus NF-κB could be 
targeted to ‘re-educate’ tumour-promoting macrophages towards an 
antitumour function. 
Basement membrane
T cell
Macrophage
Fibroblast
Epithelial cell
TAM
Tumour cell
Metastatic
tumour cell
Regulatory
T cell
Erythrocyte
Blood vessel
d  Distant metastasis
c  Local invasion
b  Carcinoma in situ
a  Normal epithelium Figure 4 | Inflammation and the malignant progression of epithelial 
tumours. a, Normal epithelium. The proliferation of epithelial cells and 
the homeostatic trafficking of leukocytes in the epithelium is regulated by 
autocrine and paracrine chemokine- and cytokine-mediated signalling. 
b, Carcinoma in situ. The extrinsic (inflammatory) pathway and the intrinsic 
(oncogenic) pathway induce the production of chemokines and cytokines. 
These factors attract a tumour-promoting infiltrate (which contains, for 
example, TAMs and regulatory T cells, as shown here), and they also promote 
angiogenesis. The expression of chemokine receptors can be induced on 
initiated cells (that is, early tumour cells). These receptors then aid in tumour-
cell survival and might be necessary (but are not sufficient) for invasion 
across the basement membrane. Both autocrine and paracrine networks of 
cytokines and chemokines are involved in these processes. c, Local invasion. 
The chemokines and cytokines continue to attract and modulate a tumour-
promoting infiltrate. They also promote angiogenesis and control tissue 
remodelling (for example, changes in the basement membrane). Operating 
in paracrine and autocrine loops, these factors induce the expression of genes 
associated with survival, invasion and migration in cells that have enough 
oncogenic changes to allow them to invade the basement membrane. The 
chemokines and cytokines are also involved in the intravasation of tumour 
cells into blood vessels and in lymphatic spread. d, Distant metastasis. The 
autocrine and paracrine chemokine- and cytokine-mediated signalling 
promotes the survival of malignant cells in distant organs, again attracting 
a tumour-promoting infiltrate and stimulating angiogenesis. 
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The importance of this balance is evident in psoriasis. Psoriasis is a 
T helper 1 (TH1)-cell-mediated disease that involves a massive accu-
mulation of neutrophils and monocytes in the skin, the latter of which 
are likely to become macrophages with an M1 phenotype, which have 
antitumour activity. Hence, the type of inflammation found in psoriasis 
does not promote the development of skin cancers because of the pres-
ence of macrophages that can destroy any nascent tumour cells. The 
dual potential of cancer-related inflammation (cancer promoting ver-
sus cancer inhibiting) may also be affected by the tissue type. In a skin 
tumour model, the overexpression of NF-κB was found to inhibit invasive 
epidermal neoplasia84, whereas blocking NF-κB activity inhibited the 
development of experimental liver and colon cancers31,32.
The concept that the activation of innate immune responses can pro-
mote a protective response to cancer is not new. In the late nineteenth cen-
tury, William Coley noted that some patients with cancer who had severe 
postoperative infections at the tumour site underwent spontaneous and 
sustained tumour regression85. He then developed Coley’s mixed toxins, 
a filtrate from cultures of Streptococcus pyogenes and Serratia marcescens, 
which was administered into the tumour or the surrounding tissues in 
patients with a range of advanced cancers. Although both the technique 
and the results were controversial, even at the time, Coley documented 
cases of the long-term survival of individuals with malignancies that 
remain a major challenge to treat now. And even before Coley’s time, 
there was evidence for the regression of cancer after certain bacterial 
infections. More recently, this approach was adapted successfully to treat 
patients with bladder cancer by administering Mycobacterium bovis bacil-
lus Calmette–Guérin (BCG). Such treatments probably trigger a ‘good’ 
inflammatory response (through TLRs) that not only promotes the differ-
entiation of monocytes into macro phages with an M1 phenotype but also 
promotes the development of a sustained and effective adaptive immune 
response to the tumour. This type of response might also contribute to suc-
cessful chemotherapy or radiotherapy, according to recent data obtained 
by Lionel Apetoh and colleagues86. After treating experimentally induced 
breast cancers, the authors found that dying tumour cells were able to 
cross-present antigen to dendritic cells in a TLR4- and MyD88-depend-
ent manner, as well as trigger protective immune responses through a 
‘danger signal’ (HMGB1), again by signalling through TLR4. However, 
when tumours were grown in mice with a mutant TLR4, the efficacy of 
chemotherapy and radiotherapy was reduced. Moreover, patients with 
breast cancer who have a mutation in TLR4 were found to have a higher 
frequency of metastasis.
The exact mechanisms by which a ‘good’ immune response can be 
reliably triggered during anticancer therapy are not entirely clear. It will 
be important to find the optimal stimuli to change a tumour-promo-
ting (TH2 cell and M2 macrophage) microenvironment to a tumour-
inhibiting (TH1 cell and M1 macrophage) microenvironment, and to 
understand the signalling mechanisms involved.
The big questions
The connection between inflammation and cancer is now generally 
accepted, but several questions remain. Some of these outstanding 
questions are listed in Box 2 and discussed in detail in this section. 
First, it is unclear whether inflammation is sufficient for the development 
of cancer. That is, can inflammation cause neoplasia in the absence of an 
exogenous carcinogenic agent? Several lines of evidence provide hints 
that it can. In a mouse model of bowel inflammation caused by IL-10 
deficiency, the frequency of DNA mutations observed in the colon in the 
absence of exogenous carcinogens was 4–5-fold greater than in IL-10-
sufficient mice87. In addition, a comparison of human tumours and 
the appropriate normal tissues showed a higher frequency of random 
mutations in tumour cells88. The only exception to the exceedingly low 
frequency of random mutations found in normal cells (< 1 × 10−8 per base 
pair) was an inflamed tissue88. One candidate for an endogenous ‘inflam-
matory carcinogen’ is reactive oxygen species. Neutrophils, for example, 
have been shown to inhibit base-excision repair in an alveolar epithelial 
cell line, an effect that is mediated by a product of myeloperoxidase activ-
ity, hypochlorous acid89. Interestingly, a poly morphism in the promoter of 
the gene encoding myeloperoxidase has been associated with resistance 
to the development of lung cancer in smo kers90. Therefore, although the 
evidence87–91 suggests that inflammation causes cancer, formal proof is 
still required.
The second issue is that diversity and plasticity are characteristics of 
chronic inflammation and its main orchestrator, macrophages. Studies 
using classic histological techniques and a variety of model systems show 
that cancer-related inflammation differs between tumour types. It will 
be important to define which cellular and molecular components are 
common to all cancer-promoting inflammatory responses, and which 
are specific to particular tissues and tumour types. 
The third issue relates to tipping the balance between cancer-
promoting inflammatory responses and cancer-inhibiting inflammatory 
responses. A key point that needs to be addressed is how to activate an 
appropriate antitumour adaptive immune response.
The fourth open question relates to MDSCs, which have recently 
emerged as an important factor in cancer-related inflammation46. The 
definition of MDSCs is operational and includes a heterogeneous set 
of cells in the peripheral blood and spleen. Are these cells a distinct 
population, or do they belong to a continuum of TAM differentiation?
Fifth, the emergence of a connection between sex steroid hormones, 
inflammation and cancer is a major conceptual advance that provides 
the first link between these two classic tumour-promoting pathways92. 
This connection between inflammation and sex steroid hormones prob-
ably reflects the interplay between inflammation and hormones during 
reproduction. Analysing this link in human cancer and its implica-
tions for resistance to hormonal therapies could have a huge impact 
in the clinic, given the widespread use of selective androgen-receptor 
modulators and selective oestrogen-receptor modulators (for example, 
tamoxifen) to inhibit the growth-stimulating effects of sex hormones 
on prostate cancer and breast cancer, respectively.
Last, the biggest question is whether knowledge about cancer-related 
inflammation can be translated into useful approaches to preventing, 
diagnosing and treating cancer. Malignant cells are ‘moving targets’ that 
can become resistant to even the most sophisticated targeted drugs. 
Using a combination therapy that attacks both malignant cells and the 
‘other half ’ of the tumour mass (that is, the inflammatory cells) could 
be more effective and might elicit long-lasting adaptive immunity to 
the transformed cells. 
Many drugs that could target cancer-related inflammation — for 
example, chemokine-receptor antagonists and cytokine-receptor antag-
onists, and COX inhibitors — are in clinical trials for other diseases. In 
terms of cancer, phase I/II trials of antagonists of IL-6, the IL-6 recep-
tor, CCL2, CCR4 and CXCR4 are underway for a range of epithelial 
and haematopoietic malignancies. The first (phase I/II) clinical trials 
of TNF-α antagonists in patients with advanced cancer have resulted 
in disease stabilization and some partial responses93–95, particularly for 
those with renal-cell carcinoma95. Also, a structural analogue of thalido-
mide, lenalidomide, that inhibits production of several inflammatory 
cytokines has been shown to be active against advanced myeloma when 
combined with dexamethasone96. In addition, COX2 inhibitors have 
been shown to prevent the recurrence of both sporadic adenomatous
1. Is inflammation sufficient for cancer development?
2. Despite the diversity of tumours and oncogenic pathways, are 
there aspects of cancer-related inflammation that are common to all  
malignancies? 
3. How can the balance between ‘bad’ inflammation and ‘good’   
inflammation be altered to favour adaptive immunity instead of tumour 
development? 
4. What is the relationship between MDSCs and TAMs? 
5. What is the clinical relevance of the connections between sex steroid  
hormones and inflammation?
6. What is the best way to target cancer-related inflammation in 
patients with cancer? This is the most difficult question. 
Box 2 | Unanswered questions about cancer-related inflammation
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polyps and adenomas in people with a genetic predisposition to 
developing these97,98. 
Drugs that target cancer-related inflammation have the potential to 
re-educate a tumour-promoting inflammatory infiltrate or to prevent 
such cells from migrating to the tumour site. They also might be able to 
‘re-align’ a tumour-promoting microenvironment to become a tumour-
inhibiting microenvironment, to encourage tumour-specific adaptive 
immune responses and to inhibit metastatic spread. This potential for 
reversing tumour-supporting inflammation could be the start of an 
exciting new era for anticancer therapies. ■ 
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